A synthetic fragment derived from the C-terminal region of human growth hormone. Research focuses on the biological properties of this fragment and its relationship to metabolic and GH-associated signalling without representing the complete GH molecule.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide derived from amino acids 176–191 of human growth hormone (hGH), with an additional tyrosine residue. It was developed to investigate the metabolic activity associated with this specific region of the growth hormone molecule, particularly its potential involvement in lipid metabolism.
AOD-9604 has been investigated in preclinical and clinical research examining lipolysis, fat oxidation and metabolic regulation. Experimental studies suggest that the peptide may influence lipid metabolism without reproducing the full growth-promoting activity of human growth hormone.
AOD-9604 is presented as an experimental research compound for laboratory and scientific applications. The stated quantity refers to the amount of compound contained in the product and should not be interpreted as a recommended human dosage.
Product: AOD-9604
Strength: 10 mg
Alternative name: Anti-Obesity Drug 9604; modified hGH fragment 176–191
Category: Metabolic
Compound classification: Synthetic growth hormone-derived peptide fragment
Research target: Lipid metabolism and adipose tissue-associated metabolic pathways
Research focus: Lipolysis, fat oxidation, adipose tissue metabolism and metabolic regulation
Mechanism: Investigated for its potential modulation of lipid metabolism through biological activity associated with the C-terminal region of human growth hormone.
Pharmacological profile: Experimental metabolic peptide investigated in preclinical and human clinical studies.
Intended use: Laboratory and research use only
A synthetic analogue of growth hormone-releasing hormone (GHRH) studied through the GHRH receptor and downstream GH/IGF-1 axis. Research areas include endocrine signalling, growth-hormone physiology and metabolic regulation.
A synthetic growth hormone secretagogue peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone signalling pathways. Its research landscape includes GH secretion, neuroendocrine regulation and metabolic signalling.
A synthetic growth hormone-releasing peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone secretory pathways. Its research landscape includes GH release, pituitary signalling and neuroendocrine regulation.
A two-component research formulation combining a GHRH-pathway analogue with a growth-hormone secretagogue, allowing investigation of two distinct signalling mechanisms converging on the GH axis. Both components and their quantities should remain explicitly identified.
A short-acting GHRH-analogue research peptide used to investigate growth-hormone-releasing pathways and GH/IGF-1 signalling. The No-DAC form must be clearly distinguished from albumin-binding CJC-1295 with DAC because their molecular designs are not equivalent.
A growth-hormone secretagogue investigated through ghrelin/GHS receptor signalling and downstream GH physiology. It provides a mechanistically different research route into the GH axis than GHRH analogues such as CJC-1295 and tesamorelin.